A United States unit of GlaxoSmithKline (GSK), Britain’s largest drugmaker, is suing Swiss rival Roche for infringing a patent.
This content was published on
1 minute
swissinfo and agencies
According to GlaxoSmithKline, Roche Holding infringes patents issued in 2008 and 2010 covering antibody purification when it produces its cancer drug Herceptin.
Roche, and its United States business Genentech, infringe the patent by “making and/or having made therapeutic antibody products, including without limitation Herceptin,” the complaint said.
Glaxo is demanding damages to compensate for violations of its patent.
Genentech declined to comment except to say that it was aware of the lawsuit and that a second lawsuit had been filed in the Northern District of California. The California lawsuit was brought by Genentech against Glaxo, according to Caroline Pecquet, a Genentech spokeswoman.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis found guilty of sex discrimination
This content was published on
At the end of a six-week trial on Monday it awarded compensatory damages of $3.3 million (SFr3.74 million) to 12 women, and punitive damages to a larger group. The class action lawsuit – representing 5,600 women – alleged that the women were discriminated against in the areas of pay, promotions, and pregnancy-related matters. They are…
This content was published on
As the Zurich-based NZZ am Sonntag newspaper reported on Sunday, many practices offering botox have been warned to adjust how they describe their services, whether in print ads or online. Clinic homepages must also comply with the law. The nerve poison was originally created to treat medical conditions like muscle spasms. Clinics offering botox for…
This content was published on
The discovery of the drug by a Swiss-led international team is particularly timely, as experts have reported in Asia the first signs of resistance to artemisinin, the essential ingredient of malaria treatments for millions of patients annually. In laboratory tests the new experimental anti-malarial drug, NITD609, which belongs to a new class of compounds called…
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.